Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA

Molecular Therapy Nucleic Acids

Volumn 1, Issue 6, 2012, Pages e27-

  Järver, Peter ^a   Coursindel, Thibault ^a   Andaloussi, Samir El ^b,c   Godfrey, Caroline ^b   Wood, Matthew Ja ^b   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antisense; Cell delivery; Oligonucleotide; Peptide; SiRNA

Indexed keywords

EID: 84868369556     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.18     Document Type: Review

References (168)

1. Kole, R, Krainer, AR and Altman, S (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140.
2. Kurreck, J (2008). Therapeutic Oligonucleotides. Royal Society of Chemistry: Cambridge.
3. Bijsterbosch, MK, Manoharan, M, Rump, ET, De Vrueh, RL, van Veghel, R, Tivel, KL et al. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25: 3290-3296. (Pubitemid 27338689)
4. Kaneda, Y (2010). Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 7: 1079-1093.
5. Xu, L and Anchordoquy, T (2011). Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 100: 38-52.
6. Derossi, D, Joliot, AH, Chassaing, G and Prochiantz, A (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450. (Pubitemid 24198241)
7. Said Hassane, F, Saleh, AF, Abes, R, Gait, MJ and Lebleu, B (2010). Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 67: 715-726.
8. Margus, H, Padari, K and Pooga, M (2012). Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20: 525-533.
9. Juliano, RL (2005). Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr Opin Mol Ther 7: 132-136. (Pubitemid 40514682)
10. Nakase, I, Akita, H, Kogure, K, Gräslund, A, Langel, U, Harashima, H et al. (2011). Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res (epub ahead of print).
11. Juliano, RL, Ming, X and Nakagawa, O (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem 23: 147-157.
12. Laakkonen, P and Vuorinen, K (2010). Homing peptides as targeted delivery vehicles. Integr Biol (Camb) 2: 326-337.
13. Zamecnik, PC and Stephenson, ML (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284. (Pubitemid 8290783)
14. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
15. Mahato, RI, Cheng, K and Guntaka, RV (2005). Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin Drug Deliv 2: 3-28. (Pubitemid 40123880)
16. Rogers, FA, Lin, SS, Hegan, DC, Krause, DS and Glazer, PM (2012). Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol Ther 20: 109-118.
17. Jepsen, JS and Wengel, J (2004). LNA-antisense rivals siRNA for gene silencing. Curr Opin Drug Discov Devel 7: 188-194. (Pubitemid 44111950)
18. Laxton, C, Brady, K, Moschos, S, Turnpenny, P, Rawal, J, Pryde, DC et al. (2011). Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother 55: 3105-3114.
19. Fabani, MM and Gait, MJ (2008). miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14: 336-346. (Pubitemid 351171593)
20. Torres, AG, Fabani, MM, Vigorito, E, Williams, D, Al-Obaidi, N, Wojciechowski, F et al. (2012). Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res 40: 2152-2167.
21. Stein, CA, Hansen, JB, Lai, J, Wu, S, Voskresenskiy, A, Høg, A et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38: e3.
22. Fabani, MM, Abreu-Goodger, C, Williams, D, Lyons, PA, Torres, AG, Smith, KG et al. (2010). Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38: 4466-4475.
23. Gambari, R, Fabbri, E, Borgatti, M, Lampronti, I, Finotti, A, Brognara, E et al. (2011). Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol 82: 1416-1429.
24. Staton, AA and Giraldez, AJ (2011). Use of target protector morpholinos to analyze the physiological roles of specific miRNA-mRNA pairs in vivo. Nat Protoc 6: 2035-2049.
25. EL-Andaloussi, S, Johansson, HJ, Lundberg, P and Langel, Ü (2006). Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 8: 1262-1273. (Pubitemid 44660525)
26. Abes, S, Moulton, H, Turner, J, Clair, P, Richard, JP, Iversen, P et al. (2007). Peptidebased delivery of nucleic acids: design, mechanism of uptake and applications to splicecorrecting oligonucleotides. Biochem Soc Trans 35(Pt 1): 53-55.
27. Wood, MJ, Gait, MJ and Yin, H (2010). RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133(Pt 4): 957-972.
28. Passini, MA, Bu, J, Richards, AM, Kinnecom, C, Sardi, SP, Stanek, LM et al. (2011). Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3: 72ra18.
29. Kang, JK, Malerba, A, Popplewell, L, Foster, K and Dickson, G (2011). Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther 19: 159-164.
30. Eckstein, F (2007). The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7: 1021-1034. (Pubitemid 47208133)
31. Levin, AA (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489: 69-84.
32. Sanghvi, YS (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr Protoc Nucleic Acid Chem Chapter 4: Unit 4.1.1-Unit 4.122.
33. Watts, JK and Corey, DR (2010). Clinical status of duplex RNA. Bioorg Med Chem Lett 20: 3203-3207.
34. Swayze, EE, Siwkowski, AM, Wancewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G et al. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35: 687-700. (Pubitemid 46232083)
35. Obad, S, dos Santos, CO, Petri, A, Heidenblad, M, Broom, O, Ruse, C et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378.
36. Moulton, HM, Moulton, JD (2008). Antisense morpholino oligomers and their peptide conjugates. In: Kurreck, J (ed). Therapeutic Oligonucleotides. Royal Society of Chemistry: Cambridge, UK. pp. 43-79.
37. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
38. Pandey, VN, Upadhyay, A and Chaubey, B (2009). Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opin Biol Ther 9: 975-989.
39. Singh, Y, Murat, P and Defrancq, E (2010). Recent developments in oligonucleotide conjugation. Chem Soc Rev 39: 2054-2070.
40. Lu, K, Duan, QP, Ma, L and Zhao, DX (2010). Chemical strategies for the synthesis of peptide-oligonucleotide conjugates. Bioconjug Chem 21: 187-202.
41. Pooga, M, Soomets, U, Hällbrink, M, Valkna, A, Saar, K, Rezaei, K et al. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 16: 857-861. (Pubitemid 28405857)
42. Lundin, P, Johansson, H, Guterstam, P, Holm, T, Hansen, M, Langel, U et al. (2008). Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem 19: 2535-2542.
43. Torres, AG and Gait, MJ (2012). Exploiting cell surface thiols to enhance cellular uptake. Trends Biotechnol 30: 185-190.
44. Ezzat, K, Helmfors, H, Tudoran, O, Juks, C, Lindberg, S, Padari, K et al. (2012). Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J 26: 1172-1180.
45. Turner, JJ, Williams, D, Owen, D and Gait, MJ (2005). Disulfide conjugation of peptides to oligonucleotides and their analogues. Curr Protocols Nucleic Acids Chemistry: 4.28.21-24 .28.21.
46. Konate, K, Crombez, L, Deshayes, S, Decaffmeyer, M, Thomas, A, Brasseur, R et al. (2010). Insight into the cellular uptake mechanism of a secondary amphipathic cell- penetrating peptide for siRNA delivery. Biochemistry 49: 3393-3402.
47. Rasmussen, FW, Bendifallah, N, Zachar, V, Shiraishi, T, Fink, T, Ebbesen, P et al. (2006). Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides 16: 43-57.
48. Futaki, S, Ohashi, W, Suzuki, T, Niwa, M, Tanaka, S, Ueda, K et al. (2001). Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12: 1005-1011. (Pubitemid 33136872)
49. Mäe, M, El Andaloussi, S, Lundin, P, Oskolkov, N, Johansson, HJ, Guterstam, P et al. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a noncovalent co-incubation strategy. J Control Release 134: 221-227.
50. Allinquant, B, Hantraye, P, Mailleux, P, Moya, K, Bouillot, C and Prochiantz, A (1995). Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol 128: 919-927.
51. Bongartz, JP, Aubertin, AM, Milhaud, PG and Lebleu, B (1994). Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22: 4681-4688. (Pubitemid 24354801)
52. Turner, Y, Wallukat, G, Säälik, P, Wiesner, B, Pritz, S and Oehlke, J (2010). Cellular uptake and biological activity of peptide nucleic acids conjugated with peptides with and without cell-penetrating ability. J Pept Sci 16: 71-80.
53. Turner, JJ, Ivanova, GD, Verbeure, B, Williams, D, Arzumanov, AA, Abes, S et al. (2005). Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res 33: 6837-6849. (Pubitemid 43000315)
54. Henke, E, Perk, J, Vider, J, de Candia, P, Chin, Y, Solit, DB et al. (2008). Peptide- conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 26: 91-100.
55. Morris, MC, Gros, E, Aldrian-Herrada, G, Choob, M, Archdeacon, J, Heitz, F et al. (2007). A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 35: e49.
56. Kang, SH, Cho, MJ and Kole, R (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37: 6235-6239. (Pubitemid 28213640)
57. Sazani, P, Kang, SH, Maier, MA, Wei, C, Dillman, J, Summerton, J et al. (2001). Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 29: 3965-3974. (Pubitemid 32962686)
58. Wu, RP, Youngblood, DS, Hassinger, JN, Lovejoy, CE, Nelson, MH, Iversen, PL et al. (2007). Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35: 5182-5191. (Pubitemid 47394201)
59. Abes, R, Moulton, HM, Clair, P, Yang, ST, Abes, S, Melikov, K et al. (2008). Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 36: 6343-6354.
60. Abes, S, Turner, JJ, Ivanova, GD, Owen, D, Williams, D, Arzumanov, A et al. (2007). Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 35: 4495-4502. (Pubitemid 47244600)
61. Laufer, SD, Recke, AL, Veldhoen, S, Trampe, A and Restle, T (2009). Noncovalent peptide-mediated delivery of chemically modified steric block oligonucleotides promotes splice correction: quantitative analysis of uptake and biological effect. Oligonucleotides 19: 63-80.
62. Rydström, A, Deshayes, S, Konate, K, Crombez, L, Padari, K, Boukhaddaoui, H et al. (2011). Direct translocation as major cellular uptake for CADY self-assembling peptidebased nanoparticles. PLoS ONE 6: e25924.
63. Moulton, HM and Moulton, JD (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798: 2296-2303.
64. Ivanova, GD, Arzumanov, A, Abes, R, Yin, H, Wood, MJ, Lebleu, B et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36: 6418-6428.
65. Koppelhus, U, Shiraishi, T, Zachar, V, Pankratova, S and Nielsen, PE (2008). Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjug Chem 19: 1526-1534.
66. Shen, G, Fang, H, Song, Y, Bielska, AA, Wang, Z and Taylor, JS (2009). Phospholipid conjugate for intracellular delivery of peptide nucleic acids. Bioconjug Chem 20: 1729-1736.
67. Alam, MR, Dixit, V, Kang, H, Li, ZB, Chen, X, Trejo, J et al. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res 36: 2764-2776. (Pubitemid 351659588)
68. Alam, MR, Ming, X, Dixit, V, Fisher, M, Chen, X and Juliano, RL (2010). The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides 20: 103-109.
69. Ming, X, Alam, MR, Fisher, M, Yan, Y, Chen, X and Juliano, RL (2010). Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res 38: 6567-6576.
70. Lehto, T, Abes, R, Oskolkov, N, Suhorutsenko, J, Copolovici, DM, Mäger, I et al. (2010). Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co- incubation strategy. J Control Release 141: 42-51.
71. Hassane, FS, Abes, R, El Andaloussi, S, Lehto, T, Sillard, R, Langel, U et al. (2011). Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release 153: 163-172.
72. Ezzat, K, Andaloussi, SE, Zaghloul, EM, Lehto, T, Lindberg, S, Moreno, PM et al. (2011). PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 39: 5284-5298.
73. Wood, MJA (2010). Towards an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci Transl Med 2: 25ps15.
74. Yin, H, Moulton, HM, Betts, C, Seow, Y, Boutilier, J, Iverson, PL et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414.
75. Yin, H, Saleh, AF, Betts, C, Camelliti, P, Seow, Y, Ashraf, S et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303.
76. Yin, H, Lu, Q and Wood, M (2008). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45.
77. Wancewicz, EV, Maier, MA, Siwkowski, AM, Albertshofer, K, Winger, TM, Berdeja, A et al. (2010). Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. J Med Chem 53: 3919-3926.
78. Boffa, LC, Cutrona, G, Cilli, M, Matis, S, Damonte, G, Mariani, MR et al. (2007). Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Ther 14: 220-226. (Pubitemid 46106965)
79. Hu, J and Corey, DR (2007). Inhibiting gene expression with peptide nucleic acid (PNA)-peptide conjugates that target chromosomal DNA. Biochemistry 46: 7581-7589. (Pubitemid 46986382)
80. Hu, J, Matsui, M and Corey, DR (2009). Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci 1175: 24-31.
81. Matsui, M and Corey, DR (2012). Allele-selective inhibition of trinucleotide repeat genes. Drug Discov Today 17: 443-450.
82. Elmén, J, Lindow, M, Schütz, S, Lawrence, M, Petri, A, Obad, S et al. (2008). LNAmediated microRNA silencing in non-human primates. Nature 452: 896-899. (Pubitemid 351550859)
83. Lanford, RE, Hildebrandt-Eriksen, ES, Petri, A, Persson, R, Lindow, M, Munk, ME et al. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
84. Oh, SY, Ju, Y and Park, H (2009). A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol Cells 28: 341-345.
85. Oh, SY, Ju, Y, Kim, S and Park, H (2010). PNA-based antisense oligonucleotides for micrornas inhibition in the absence of a transfection reagent. Oligonucleotides 20: 225-230.
86. Turner, JJ, Jones, S, Fabani, MM, Ivanova, G, Arzumanov, AA and Gait, MJ (2007). RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis 38: 1-7. (Pubitemid 44960863)
87. Hsu, T and Mitragotri, S (2011). Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci USA 108: 15816-15821.
88. Alam, MR, Ming, X, Fisher, M, Lackey, JG, Rajeev, KG, Manoharan, M et al. (2011). Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem 22: 1673-1681.
89. Meade, BR and Dowdy, SF (2008). Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 60: 530-536.
90. Crombez, L, Morris, MC, Dufort, S, Aldrian-Herrada, G, Nguyen, Q, Mc Master, G et al. (2009). Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 37: 4559-4569.
91. Divita, G, Heitz, F, Morris, MC and Aldrian-Herrada, G (2009). Cell-penetrating peptides for intracellular delivery of molecules, US Patent 2009/015603 (ed).
92. Crombez, L, Aldrian-Herrada, G, Konate, K, Nguyen, QN, McMaster, GK, Brasseur, R et al. (2009). A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17: 95-103.
93. Arthanari, Y, Pluen, A, Rajendran, R, Aojula, H and Demonacos, C (2010). Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. J Control Release 145: 272-280.
94. EL-Andaloussi, S, Lehto, T, Mäger, I, Rosenthal-Aizman, K, Oprea, II, Simonson, OE et al. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 39: 3972-3987.
95. Eguchi, A, Meade, BR, Chang, YC, Fredrickson, CT, Willert, K, Puri, N et al. (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27: 567-571.
96. Michiue, H, Eguchi, A, Scadeng, M and Dowdy, SF (2009). Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8: 2306-2313.
97. Chaubey, B, Tripathi, S and Pandey, VN (2008). Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides 18: 9-20.
98. Böttcher-Friebertshäuser, E, Stein, DA, Klenk, HD and Garten, W (2011). Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J Virol 85: 1554-1562.
99. Lai, SH, Stein, DA, Guerrero-Plata, A, Liao, SL, Ivanciuc, T, Hong, C et al. (2008). Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther 16: 1120-1128. (Pubitemid 351737078)
100. Opriessnig, T, Patel, D, Wang, R, Halbur, PG, Meng, XJ, Stein, DA et al. (2011). Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptideconjugated morpholino oligomer. Antiviral Res 91: 36-42.
101. Burrer, R, Neuman, BW, Ting, JP, Stein, DA, Moulton, HM, Iversen, PL et al. (2007). Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J Virol 81: 5637-5648. (Pubitemid 46847003)
102. Deas, TS, Bennett, CJ, Jones, SA, Tilgner, M, Ren, P, Behr, MJ et al. (2007). In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 51: 2470-2482. (Pubitemid 47047326)
103. Splith, K and Neundorf, I (2011). Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J 40: 387-397.
104. Good, L and Nielsen, PE (1999). Peptide nucleic acid (PNA) antisense effects in Escherichia coli. Curr Issues Mol Biol 1: 111-116.
105. Tilley, LD, Hine, OS, Kellogg, JA, Hassinger, JN, Weller, DD, Iversen, PL et al. (2006). Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture. Antimicrob Agents Chemother 50: 2789-2796. (Pubitemid 44198702)
106. Tilley, LD, Mellbye, BL, Puckett, SE, Iversen, PL and Geller, BL (2007). Antisense peptidephosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. J Antimicrob Chemother 59: 66-73. (Pubitemid 46017902)
107. Mellbye, BL, Puckett, SE, Tilley, LD, Iversen, PL and Geller, BL (2009). Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 53: 525-530.
108. Wesolowski, D, Tae, HS, Gandotra, N, Llopis, P, Shen, N and Altman, S (2011). Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by genespecific and nonspecific modes. Proc Natl Acad Sci USA 108: 16582-16587.
109. Mellbye, BL, Weller, DD, Hassinger, JN, Reeves, MD, Lovejoy, CE, Iversen, PL et al. (2010). Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. J Antimicrob Chemother 65: 98-106.
110. Goh, S, Boberek, JM, Nakashima, N, Stach, J and Good, L (2009). Concurrent growth rate and transcript analyses reveal essential gene stringency in Escherichia coli. PLoS ONE 4: e6061.
111. Bai, H, You, Y, Yan, H, Meng, J, Xue, X, Hou, Z et al. (2012). Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted to rpoD gene. Biomaterials 33: 659-667.
112. Inaki, Y, Ishikawa, T and Takemoto, K (1980). Synthesis and interactions of poly-L-lysines containing nucleic acid bases. Nucleic Acids Symp Ser: s137-s140.
113. Boussif, O, Lezoualc'h, F, Zanta, MA, Mergny, MD, Scherman, D, Demeneix, B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
114. Wightman, L, Kircheis, R, Rössler, V, Carotta, S, Ruzicka, R, Kursa, M et al. (2001). Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med 3: 362-372. (Pubitemid 33691776)
115. Plank, C, Oberhauser, B, Mechtler, K, Koch, C and Wagner, E (1994). The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem 269: 12918-12924. (Pubitemid 24202092)
116. Merkel, OM, Librizzi, D, Pfestroff, A, Schurrat, T, Buyens, K, Sanders, NN et al. (2009). Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-gpoly (ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138: 148-159.
117. Wagner, E (2011). Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res (epub ahead of print).
118. Hatakeyama, H, Akita, H and Harashima, H (2011). A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63: 152-160.
119. Creusat, G, Rinaldi, AS, Weiss, E, Elbaghdadi, R, Remy, JS, Mulherkar, R et al. (2010). Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA delivery systems. Bioconjug Chem 21: 994-1002.
120. Zaghloul, EM, Viola, JR, Zuber, G, Smith, CI and Lundin, KE (2010). Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine. Mol Pharm 7: 652-663.
121. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569. (Pubitemid 351668042)
122. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
123. Ogris, M (2006). Nucleic acid based therapeutics for tumor therapy. Anticancer Agents Med Chem 6: 563-570. (Pubitemid 44697114)
124. Ogris, M and Wagner, E (2011). To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum Gene Ther 22: 799-807.
125. Kilk, K, El-Andaloussi, S, Järver, P, Meikas, A, Valkna, A, Bartfai, T et al. (2005). Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J Control Release 103: 511-523. (Pubitemid 40342545)
126. Kleemann, E, Dailey, LA, Abdelhady, HG, Gessler, T, Schmehl, T, Roberts, CJ et al. (2004). Modified polyethylenimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J Control Release 100: 437-450. (Pubitemid 39572923)
127. Sirsi, SR, Schray, RC, Guan, X, Lykens, NM, Williams, JH, Erney, ML et al. (2008). Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum Gene Ther 19: 795-806.
128. Schiffelers, RM, Ansari, A, Xu, J, Zhou, Q, Tang, Q, Storm, G et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149.
129. Wang, XL, Xu, R and Lu, ZR (2009). A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J Control Release 134: 207-213.
130. Tietze, N, Pelisek, J, Philipp, A, Roedl, W, Merdan, T, Tarcha, P et al. (2008). Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. Oligonucleotides 18: 161-174. (Pubitemid 352019749)
131. Dohmen, C and Wagner, E (2011). Multifunctional CPP polymer system for tumor-targeted pDNA and siRNA delivery. Methods Mol Biol 683: 453-463.
132. Meyer, M, Philipp, A, Oskuee, R, Schmidt, C and Wagner, E (2008). Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J Am Chem Soc 130: 3272-3273. (Pubitemid 351456015)
133. Meyer, M, Dohmen, C, Philipp, A, Kiener, D, Maiwald, G, Scheu, C et al. (2009). Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol Pharm 6: 752-762.
134. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
135. Davis, ME (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6: 659-668.
136. Scheule, RK, St George, JA, Bagley, RG, Marshall, J, Kaplan, JM, Akita, GY et al. (1997). Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 8: 689-707. (Pubitemid 27202056)
137. Filion, MC and Phillips, NC (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329: 345-356. (Pubitemid 27466823)
138. Torchilin, VP (2008). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60: 548-558. (Pubitemid 351215572)
139. Ambegia, E, Ansell, S, Cullis, P, Heyes, J, Palmer, L and MacLachlan, I (2005). Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 1669: 155-163. (Pubitemid 40704733)
140. Hayashi, Y, Yamauchi, J, Khalil, IA, Kajimoto, K, Akita, H and Harashima, H (2011). Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int J Pharm 419: 308-313.
141. Tagalakis, AD, He, L, Saraiva, L, Gustafsson, KT and Hart, SL (2011). Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 32: 6302-6315.
142. Nakamura, Y, Kogure, K, Yamada, Y, Futaki, S and Harashima, H (2006). Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide. J Pharm Pharmacol 58: 431-437.
143. Nakamura, Y, Kogure, K, Futaki, S and Harashima, H (2007). Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 119: 360-367. (Pubitemid 46770881)
144. Akita, H, Kogure, K, Moriguchi, R, Nakamura, Y, Higashi, T, Nakamura, T et al. (2010). Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 143: 311-317.
145. Hatakeyama, H, Akita, H, Ito, E, Hayashi, Y, Oishi, M, Nagasaki, Y et al. (2011). Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32: 4306-4316.
146. Zhang, C, Tang, N, Liu, X, Liang, W, Xu, W and Torchilin, VP (2006). siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112: 229-239.
147. Trabulo, S, Resina, S, Simões, S, Lebleu, B and Pedroso de Lima, MC (2010). A noncovalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J Control Release 145: 149-158.
148. Ratajczak, J, Wysoczynski, M, Hayek, F, Janowska-Wieczorek, A and Ratajczak, MZ (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20: 1487-1495. (Pubitemid 44264090)
149. Camussi, G, Deregibus, MC, Bruno, S, Grange, C, Fonsato, V and Tetta, C (2011). Exosome/ microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res 1: 98-110.
150. Valadi, H, Ekström, K, Bossios, A, Sjöstrand, M, Lee, JJ and Lötvall, JO (2007). Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659. (Pubitemid 47214727)
151. Skog, J, Würdinger, T, van Rijn, S, Meijer, DH, Gainche, L, Sena-Esteves, M et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
152. Pegtel, DM, Cosmopoulos, K, Thorley-Lawson, DA, van Eijndhoven, MA, Hopmans, ES, Lindenberg, JL et al. (2010). Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 107: 6328-6333.
153. Montecalvo, A, Larregina, AT, Shufesky, WJ, Stolz, DB, Sullivan, ML, Karlsson, JM et al. (2012). Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119: 756-766.
154. Alvarez-Erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S and Wood, MJ (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345.
155. Quah, BJ and O'Neill, HC (2005). The immunogenicity of dendritic cell-derived exosomes. Blood Cells Mol Dis 35: 94-110. (Pubitemid 41267035)
156. Lentz, TL (1990). Rabies virus binding to an acetylcholine receptor alpha-subunit peptide. J Mol Recognit 3: 82-88.
157. Maier, MA, Esau, CC, Siwkowski, AM, Wancewicz, EV, Albertshofer, K, Kinberger, GA et al. (2006). Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J Med Chem 49: 2534-2542.
158. Du, L, Kayali, R, Bertoni, C, Fike, F, Hu, H, Iversen, PL et al. (2011). Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 20: 3151-3160.
159. Jearawiriyapaisarn, N, Moulton, HM, Buckley, B, Roberts, J, Sazani, P, Fucharoen, S et al. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629.
160. Heemskerk, H, de Winter, C, van Kuik, P, Heuvelmans, N, Sabatelli, P, Rimessi, P et al. (2010). Preclinical PK and PD studies on 2'-O-methyl- phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18: 1210-1217.
161. Moschos, SA, Jones, SW, Perry, MM, Williams, AE, Erjefalt, JS, Turner, JJ et al. (2007). Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18: 1450-1459. (Pubitemid 47464052)
162. Wu, B, Moulton, HM, Iversen, PL, Juang, J, Li, J, Spurney, CF et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modifies morpholino oligomer. Proc Natl Acad Sci USA 105: 14814-14819.
163. Sazani, P, Ness, KP, Weller, DL, Poage, DW, Palyada, K and Shrewsbury, SB (2011). Repeat- dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int J Toxicol 30: 313-321.
164. Sazani, P, Ness, KP, Weller, DL, Poage, D, Nelson, K and Shrewsbury, AS (2011). Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol 30: 322-333.
165. Amantana, A, Moulton, HM, Cate, ML, Reddy, MT, Whitehead, T, Hassinger, JN et al. (2007). Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide- morpholino oligomer conjugate. Bioconjug Chem 18: 1325-1331. (Pubitemid 47122656)
166. Aguilera, TA, Olson, ES, Timmers, MM, Jiang, T and Tsien, RY (2009). Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 1: 371-381.
167. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
168. Muntoni, F and Wood, MJ (2011). Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10: 621-637.